Introduction {#S1}
============

Depression is the leading cause of disability worldwide ([@B65]). Nowadays, it is judged to affect more than 320 million people of all ages and genders ([@B62]), even though it is more frequent in women than man ([@B15]).

Currently, and according to DSM-5 ([@B3]), there are eight main forms of depression: major depressive disorder (MDD), persistent depressive disorder, premenstrual dysphoric disorder, disruptive mood dysregulation disorder, substance/medication-induced depressive disorder, depressive disorder due to another medical condition, non specified depressive disorder, and other specified depressive disorder. MDD is the most severe, prevalent, and disabling depression type ([@B37]). It is characterized by a persistent depressed mood or loss of pleasure, along with four out of the following symptoms: significant weight loss or gain; insomnia or hypersomnia; psychomotor agitation or retardation; fatigue or loss of energy; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think, concentrate, or make decisions; recurrent thoughts of death ([@B3]). For MDD to be diagnosed, the patient needs to fulfill five diagnostic criteria out of a pool of nine, which means that the same disorder may present differently in different subjects ([@B26]). The variety of both symptoms and biomarkers has led to the recent suggestion that there might be several subtypes of MDD ([@B6]).

MDD etiology is not completely understood yet. Most authors agree that there is a combination of biological and environmental factors that determine the triggering of the disorder ([@B38]). Biological factors to take into account include genes, neurotransmitters, and hormones, while environmental factors include childhood trauma, stressful life events, sexual abuse, low educational attainment, and differences in personality traits.

Evidence suggests that there are genetic factors involved, but even though more than 100 candidate genes have been investigated, a clear connection between specific genes and MDD has not yet been established ([@B54]). Furthermore, studies suggest that variations in different genes, each with a minor effect, combine to increase the risk of developing this disorder ([@B66]). Most studies suggest that MDD patients have imbalanced brain chemistry at neurotransmitters level ([@B6]). Among those, the majority of the studies indicate dopamine, norepinephrine, and serotonin as the most implicated in MDD etiology ([@B7]). Others stress the involvement of glutamate ([@B52]). Nonetheless, some studies find no differences in neurotransmitters between MDD patients and healthy controls (for a review, see [@B6]). Similarly, it is widely accepted that hormones play a role in MDD etiology ([@B13]) but there is no clear-cut connection between a specific hormone secretion and MDD. For example, [@B4] found differences between MDD patients and healthy controls in hormone levels of adrenocorticotropic hormone, testosterone, thyroid--stimulating hormone, free thyroxine index, and cortisol/dehydroepiandrosterone sulfate (DHEA--S), while others consider vasopressin and oxytocin to play a pivotal role in MDD etiology (for a review, see [@B25]).

Recent studies also suggest that there is a link between inflammation and MDD, suggesting that MDD has an inflammatory subtype ([@B6]), but the claims that inflammation has a role in etiology of MDD are still being disputed ([@B40]). The same happens with changes in gut microbiome in MDD patients ([@B64]). While the link between gut microbiome and depression is well documented, the question of the causality in the connection between the two remains to be robustly answered ([@B64]). It is important to mention that these patterns may be true for all biological changes found in MDD patients. It is almost impossible to determine if the biological changes caused MDD or if MDD caused the biological changes. Conversely, most environmental factors involved in MDD are definitely a primary cause. In this regard, the big unanswered question that remains is why does the same life event trigger MDD in one person and not in another.

Among the most documented environmental factors linked to MDD are childhood traumas, which also cause biological changes in the brain of MDD patients ([@B67]), stressful life events, sexual abuse, low educational attainment ([@B47]), and personality traits ([@B8]). Other disorders and traits are also strong predictors for MDD. For example, a big longitudinal study showed that people who present anxiety traits in their twenties are more prone to develop MDD in their thirties ([@B21]). Also Parkinson's, Migrains', Alzheimer's patients, among others, have high prevalence of MDD ([@B27]; [@B42]; [@B58]).

It is not always possible to determine a proximal cause. MDD may have seasonal or peri-partum onset, as well as being induced by other disorders (e.g., Parkinson's) or substance ingestion, but it can also emerge without an obvious reason ([@B3]).

Major depressive disorder pathogenesis is as diverse as its etiology. Even though there are several different treatment courses available (for a review, see for example [@B44]), 50--60% of patients develop treatment resistant depression, i.e., do not enter remission even after trying different courses of treatment ([@B31]), and only 52% of patients achieve a full recovery ([@B43]).

Due to its complexity, MDD is particularly hard to study, but its severity, prevalence, and significant economic burden make it a moral and social imperative to keep investing this research field. Yet, its research funding has been scarce when compared to other disorders (e.g., cancer) ([@B34]).

Randomized controlled trials (RCTs) are considered to be the gold standard for empirical research ([@B22]), namely, in MDD's potential treatments and interventions ([@B41]) but they are unsuitable for all purposes. Some authors consider observational longitudinal studies to be more useful in understanding the etiology and pathogenesis of human disorders ([@B18]) pointing out that they also overcome ethical and practical limitations of RCTs such as the insufficient study duration or the disregard of unpredictable variables that affect patients in their daily lives ([@B56]). Others stress the importance of basic and applied research aiming to understand MDD's mechanisms in a controlled environment (e.g., [@B45]).

In this regard, advanced magnetic resonance imaging techniques used in patients and healthy controls can be a powerful tool regarding the physiological and metabolic characterization of brain tissue, in the same way that single photon emission computed tomography and positron emission tomography imaging modalities provide valuable data on brain function and activity ([@B59]).

Post-mortem studies as well as cell-based disease modeling are another valuable set of tools in understanding the biology of psychiatric disorders. As cellular biology techniques evolve new ways to generate and preserve human cells *in vitro* emerge (e.g., induced pluripotent stem cells, trans differentiation technologies for deriving neurons from adult humans, [@B61]). However, they are insufficient to fully understand the pathways and progression of complex disorders. Some authors assert that systems biology might be the answer as it can integrate and model different levels of human experimental data---molecular, cellular, tissue, organ, clinical, and population disorders ([@B33]). Others suggest a mind-brain paradigm that combines simultaneous use of imaging techniques with the use of scales and/or other tests validated for psychodiagnostics as a way to build a bridge between neuroscience and psychological sciences to study mental disorders ([@B57]). Others claim that the only way to overcome such limitations is by resorting to animal models, which are seen by some as crucial for MDD research (e.g., [@B63]; [@B2]), despite their well-recognized limitations with respect to human predictability ([@B2]).

To overcome these limitations, combinations of different animal models are proposed ([@B2]), different transgenic lines of rats are generated (as described by [@B5]) and efforts are made to overcome the biological differences between species that keep emerging as extrapolation barriers ([@B23]). All the above involve high economic costs and consume a tremendous amount of animal lives. The reason behind this is because it is assumed that animal use is unavoidable and its withdrawal would jeopardize human health. However, very few studies have addressed the contribution of animal models to MDD research through significant critical scrutiny within peer-reviewed literature. Specifically, to our knowledge, the contribution of rats for this aim has never been evaluated in such terms, even though rodents are undoubtedly the most frequently used animals regarding this context. Even though mice are by far the most used rodents in biomedical research, an initial search in PubMed, a search engine that comprises more than 30 million biomedical literature publications, indicated that species within genus Rattus were highly used in MDD research, which made them an interesting case study. To evaluate the contribution of animal models to MDD research is important for ethical and economic reasons. As a society, we should make an informed decision on whether we should proceed improving animal models until we find a suitable one or if we should halt the current paradigm and invest more in other methods that might be more promising as well as cheaper and less ethically contentious ([@B10]).

To conduct such evaluation, we performed a citation analysis on original publications describing rat data within MDD research. A citation analysis as defined by [@B19] consists of determining the number of citations target papers (in this case original papers using rat models to study MDD) receive, as well as determining citation patterns---in this case which sort of papers are citing the target papers (e.g., animal research papers, human research papers, review papers). Granting that the studies cited guide and influence authors' work ([@B9]) and that citation level has been related to clinical relevance in the past ([@B48]), such citation analysis can be used as an indicator to evaluate the contribution of rat studies to current clinical knowledge in MDD, as has been done for other disorders (e.g., [@B28]; [@B36]; [@B11]) as well as for other species in regard to MDD research ([@B10]).

If rat studies are informing the human medical research community, then we would expect that:

1.  Most of the papers would be cited at least once in subsequent human medical papers;

2.  The proportion of citations by human medical papers would be substantially higher when compared to other research categories.

Methods {#S2}
=======

The citation analysis was performed between January and August of 2019. PubMed and SCOPUS were searched for publications using rat models to investigate MDD. We searched PubMed using Medical Subject Heading search terms (MeSH terms): "Depressive Disorder, Major" AND "rat" OR "rodent." MeSH terms are a comprehensive list of key terms made available by PubMed designed to identify all relevant studies in an area ([@B60]). So, searching for "MDD" retrieves other nomenclatures for the same disorder such as melancholia. Similarly, the search term "rat" retrieves papers using all rat species. We used PubMed filters to exclude review articles ("review," "systematic review," "meta-analysis," "bibliography") as well as opinion articles ("biography," "auto-biography," "comment," "editorial," "interview"). Since Scopus does not have the MeSH term tool, we used the search terms "MDD" AND ("rat" OR "rattus") in the search fields. We included journal papers, books, research reports, and conference proceedings written in English or Portuguese, which are within our language proficiencies. We restricted our search to publications prior to 31 December 2013, to allow adequate time for citation of articles to occur. We did not include a lower date limit.

Since our goal was to evaluate the contribution of animal models---particularly rat models---to current clinical knowledge of MDD, we manually excluded from our analysis all the papers that reported animal and human data, as well as papers reporting other species' data (e.g., mice). Hence, we included only original papers focused on MDD, exclusively using data obtained from rats. We excluded papers describing other disorders, data from other species along with data from rats, and papers that did not present first hand data (e.g., review papers). Out of 237 papers originally located through the search engines' filters, we manually excluded 59 because they met exclusion criteria.

The retrieved papers were subjected to a subsequent citation analysis using the cited reference search facility within Scopus and Web of Science.

Web of Science is a major scientific citation indexing service that encompasses over 50,000 scholarly books, 12,000 journals, and 160,000 conference proceedings. Scopus is the largest citation database; it covers nearly 36,377 titles from approximately 11,678 publishers.

For each rat study, we recorded the total number of times it was cited, and allocated each citation to one or more of seven categories, defined prospectively:

1.  Animals. This category included all animal studies from observational ethological studies to invasive procedures as defined by [@B29], i.e., interfering with bodily integrity (whether through puncture or incision) or production of genetically modified animals. This category also included severe procedures (as defined by current European Legislation Directive 2010/63/EU) commonly used in mental disorder research such as inescapable electroshock or isolating social animals for long periods. We recorded within this category which animal papers focused on MDD and which focused on other subjects.

2.  Humans. This category included papers that used human participants. They included clinical or treatment trials (either drug trials or non-pharmacological treatments), papers aiming to explore psychological, social, biochemical, physiological, genetic, or neurological variables related to MDD or other human disorders; as well as papers aiming to understand the relationship between MDD and other disorders (co-morbidities) in human patients. We recorded within this category which human papers focused on MDD and which focused on other disorders.

3.  Reviews. This category included narrative reviews, systematic reviews, meta-analysis, as well as extensive opinion papers that did not report original empirical data. We included reviews focused on animals and on humans alike.

4.  Editorials. This category included editorials, comments, and clinical guides.

5.  *In vitro*. This category included exclusively cell-line data. Whenever the source of the tissue or cell was a human participant (either alive or post-mortem) or a laboratory animal killed for such purpose the paper was allocated into "human paper" or "animal research paper," respectively.

6.  *In silico*. This category included data obtained via computer simulations of human data.

7.  Social. This category included human surveys or other social perception papers.

Whenever it was not possible to define the category of the citing paper (due to language barriers---i.e., papers written in a language that was not English or Portuguese---or absence of the abstract), the paper was denoted "not available" and removed from the sample. If more than one category could be assigned to a citing paper (e.g., animal research and human paper), then that paper was allocated to every appropriate category.

To evaluate if the proportions of citations made by human publications and animal publications on MDD were different, we used a *t*-test. Results were considered statistically significant when *P* \< 0.05. The analyses were performed in R 3.6.1 ([@B50]).

Results {#S3}
=======

The 178 original rat studies focused on MDD that were published before the end of 2013 were cited 8,712 times by August 2019. Of these 178, 87 (49%) studies were never cited in subsequent publications describing human studies on MDD, and 53 (30%) were never cited in any publications related to human research, either focused on MDD, or on other disorders such as post-traumatic stress disorder or bipolar disorder.

As shown in [Figure 1](#F1){ref-type="fig"}, rat studies were mainly cited by other animal research papers (4,641), followed by review papers (2,909), human studies (794), *in vitro* papers (211), editorials (58), *in silico* papers (57), and human social papers (one). 230 citations were unavailable to us due to access or language barriers. These were removed from further analysis.

![Frequency of citations by category established in this study.](fpsyg-11-01486-g001){#F1}

The proportion of citations by human medical papers was 9.1% while the proportion of citations by animal papers was 53.3%. This corresponds to a mean difference between the proportions of citations by human and by animal papers of −46% (*p* \< 0.001). Beyond the statistical significance, this is certainly a considerable practical difference that reflects almost 100^∗^(53.3--9.1)/53.3 less citations by human papers than by animal papers.

Discussion {#S4}
==========

The majority of the rat papers located in this study were cited by subsequent animal research papers, but about half (49%) of the original papers retrieved were never cited in subsequent papers related to MDD in humans, and in fact about a third (30%) were never cited in any subsequent human studies.

Our citation analysis revealed that only around a tenth (9.1%) of the total number of citations were by human medical papers. This result contradicted the hypothesis that the proportion of citations by human medical papers would be substantially higher when compared to other research categories. This hypothesis was based on the assumption that animal models are essential to clinical research, as promulgated by several authors (e.g., [@B63]; [@B2]). Hence, our results raise doubts about the justification for these animal studies.

The results of our study are in agreement with previous studies that empirically evaluated the contribution of animal models to human healthcare either through citation analysis (e.g., [@B55]; [@B28]; [@B36]; [@B11]) either through other methods such as systematic reviews (e.g., [@B46]), social science studies (e.g., [@B55]; [@B12]), historical analysis (e.g., [@B39]), among others (for an extensive review on this topic see, for example, [@B30]).

This suggests that biomedical research resorting to animal models is not normally considered significant, or particularly visible to, the human medical research community.

Supporters of animal models of human disorders claim that this happens: (a) due to differences in the way basic animal work and human clinical trials are conducted, and propose a change to a translational biomarker-based approach within early steps of pre-clinical research ([@B20]); or that this occurs (b) due to failings in study design, conduct, analysis, and reporting (as described by [@B49]), which could be resolved with better reporting and better methodological quality (as proposed by [@B14]).

Opponents of the use of animal models point out that animal models lack external validity, i.e., findings derived in one setting, population, or species cannot be reliably applied to other settings, populations, and species, which is unavoidable since animal models: (a) oversimplify complex human disorders and the conditions in which they occur ([@B57]; [@B49]); (b) are unsuitable models due to species differences, proposing as a possible solution a shift toward human-based non-clinical research ([@B49]).

This paradigm change toward human-based research is gaining more and more supporters both for ethical and scientific reasons (e.g., [@B32]; [@B33]; [@B49]; [@B51]). But the resistance from animal researchers in face of this shift remains significant and is evident not only in the slowness to recognize the growing body of evidence against the use of animals as models, but also in the emphasis placed on refinement of animal use ([@B16]) (the third R as defined by [@B53], instead of on the first and most important R---replacement with non-animal alternatives). Considering this, [@B17] proposed that animal experimentation constitutes a good example of path dependency, which is a well-documented phenomenon that states that what has occurred in the past persists because of resistance to change.

Our results also show that more than half (53%) of the citations our target papers received were by subsequent animal papers, which strengthens the likelihood of the path dependency phenomenon described above. It can be argued that there is a need to have a substantial amount of animal research before achieving a critical mass that can lead to useful breakthroughs in human health, which might explain the high level of citations of animal papers by subsequent animal papers. Nonetheless, it does not explain the low level of citations by human papers, especially when this does not appear to be a trend in human-based approaches (*in vitro* and *in silico*) which received more citations by human medical papers in a small study previously conducted ([@B10]). Furthermore, a recent citation analysis in another field of human health research also found *in vitro* papers to be the most cited papers, above reviews, and animal experimentations papers ([@B1]).

We acknowledge that this study has certain limitations. Even though we used two very large bibliographic databases to attempt to locate all publications that met our search criteria, we acknowledge that a small minority of relevant papers may not have been retrieved (e.g., due to labeling errors) or may have been excluded due to human error, as only one person selected which retrieved papers met exclusion criteria.

Similarly, we did not take note of certain citations such as self-citations, in-house citations (i.e., citations by colleagues from the same insitution), and content-irrelevant citations (e.g., the paper is cited for other reasons other than its content). Such citation types were not considered significant in several studies and were similarly dismissed in recent studies ([@B24]).

Also, we did not analyze the quality of citing papers as in previous studies ([@B11], [@B10]). This might have resulted in an even lower, but a truer, indication of the contribution of rat models for current clinical knowledge of MDD, given that not all were likely of high quality.

Finally, we acknowledge that being cited by human medical papers is not the only indicator of the clinical usefulness of research. Uncited studies may also contribute, for example, through direct transfer of knowledge between scientists and clinicians. Most clinicians are not involved in research, i.e., they do not publish; hence, it is possible that practitioners involved in the treatment of MMD are informed by or utilize findings from rat studies through direct transfer of knowledge. A citation analysis does not measure this effect. However, it is also possible that clinicians are less aware of research results, than researchers. Thus, a survey on practitioners---which we did not perform---would have been an interesting complement to our results.

Review papers on depression that might inspire authors likely cite animal papers, nonetheless if the animal paper is really relevant for the authors' hypothesis or method it is likely the primary paper will be cited and not solely the review paper that referred to it.

Citation rates may also be affected by factors such as article length, number of authors, their country, and university of affiliation ([@B35]). Despite their limitations, however, citation frequencies do normally provide reasonably objective approximation of the importance of research results within a field. Research that makes a significant contribution---such as by confirming or refuting important hypotheses---is likely to be cited by subsequent papers. Research that is inconclusive or lacking in significance is much less likely to be cited.

Accordingly, we believe that our citation analysis provides a valid and critical assessment of the contribution of rat models to current clinical knowledge of MDD. Such evaluation of the efficacy of research approaches is important to ensure the most responsible allocation of research funds and scientific resources, to maximize the likelihood of clinical benefit to patients, and to minimize the consumption of animal lives in research where such benefits are unlikely.
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